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Abstract
With advances in care, the median age for the 
mild-moderate hemophilic patients has almost 
reached parity with the general population. 
However, they have a much higher rate of 
cardiovascular disease than their peers. The 
authors here present a successful case of a 
patient with mild hemophilia undergoing 
coronary artery bypass grafting (CABG) and 
summarize the recommendations surrounding 
the management of hemophilia in the 
perioperative setting.
Introduction 
Hemophilia A is an x-linked inherited 
manifested by excessive or spontaneous 
bleeding. As the clinical management has 
improved, the median life expectancy for 
patient with hemophilia has increased from 
7.8 years in 1930s to 75 years in 1990s 
among mild-moderate disease states.1,2 At 
the same time, patients over age 35 with 
hemophilia experienced approximately 
twice the prevalence of coronary artery 
disease (CAD), stroke and myocardial 
Hispanic white male population.3 Since the 
guidance of perioperative management of 
the cardiac surgical patient with hemophilia 
is currently limited to case reports, it is 
important to continue to report these cases. 
Many procedures required for the treatment 
of cardiovascular disease require some 
degree of anticoagulation, which can be very 
challenging in this population. Management 
of anticoagulation in patients that require 
cardiac surgery and cardiopulmonary bypass 
(CPB) can be extremely complex. There 
are currently no guidelines to direct the 
hematologic management of patients in this 
scenario. We present one case that describes 
the perioperative management of a patient 
with mild hemophilia A undergoing coronary 
artery bypass graft (CABG) with CPB. 
Case
This patient is a 41-year-old male with past 
A with recently diagnosed CAD scheduled 
45%. After consultation with hematologist, 
the following peri-operative management plan 
was devised for the patient and summarized in 
should receive a bolus of recombinant factor 
dose infusion intra and postoperatively to 
80-100%. 
of surgery was noted to be 15% (Fig. 1). The 
patient received a bolus of recombinant factor 
whole blood which was anticoagulated with 
an adenosine-calcium-dextrose solution was 
collected into a storage bag prior to incision. 
The pre-CPB period was uneventful and as 
decided preoperatively, an additional bolus 
prior to initiation of CPB. The additional 
bolus dose was used to maintain circulating 
factor levels in the setting of hemodilution 
from the CPB priming volume, which was 
approximately 800 ml. Aminocaproic acid 
infusion was used throughout the case 
at 1 gram/hour as standard thrombolytic 
prophylaxis. Heparinization was completed 
per our institutional protocols with 400 units/
kg. Multiple thromboelastograms (TEG) were 
also drawn intraoperatively to help guide the 
need for transfusions. The surgical course 
bleeding and hypotension occurred during the 
initial attempt at separation from CPB. The 
before heparinization, was 105% but could 
not be reassessed whilst on CPB due to 
heparin interfering with the laboratory assay 
factor activity was low, and recognizing the 
inability to determine activity, the patient was 
patient also received one unit of autologous 
Table 1.
Pre-Op • Recombinant factor VIII 45 IU/kg bolus pre-operatively 
• Calculated as (100-15)x0.5=42.5 (rounded by pharmacy to 45 IU/kg)
Intra-Op • 3 IU/kg/hr infusion intra and post-operatively, can be increased by 1 IU if needed 
• Considering the increased volume of distribution, another bolus of 25IU/kg was 
administered after discussing the effect that CPB priming solution and CPB circuit would 
have on the circulating blood volume
• Draw random post-operative level 
Post-Op • 
• Day 4-10: 30 IU/kg q12-24h 
• Day 11-14 (or longer based on wound healing): 20-30 IU/kg q12-24h 
Figure 1. Illustrations of perioperative interventions and pertinent lab results.
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red blood cells (RBCs), fresh frozen plasma 
(FFP), and two units of cryoprecipitate. After 
control of bleeding, the patient was then able 
to be separated from CPB without incident. 
The total blood loss for the case was 2 L, 
and 1L of cell saver was returned to patient 
post-operative (POD) day 1 and remained 
>100% through POD #3, at which time the 
infusion was stopped and bolus dosing was 
resumed. One unit of packed red blood cell 
(PRBC) was administered on POD 3, and 
no additional blood product was needed 
afterward. He remained on bolus factor 
consent was obtained to utilize this case for 
educational purposes.
administration have been reported, ranging 
from several bolus doses to a combination 
of bolus doses and continuous infusions 
activity levels.4 Despite what should have 
been adequate factor activity levels, increased 
rates of bleeding still occur in this patient 
study, 12% of the studied population had 
to undergo re-operation due to bleeding 
complications as compared to 1.9% of 
patients undergoing CABG without a bleeding 
disorder.5
acid, or aminocaproic acid should also be 
considered as adjuvant for hemostasis, as it 
has been shown to improve the clot stability 
in hemophilia A patients when combined with 
6 
prior to proceeding with a high-risk operation. 
in advance and consultation with hematology 
was done to establish baseline activity levels 
and develop an approach to address bleeding. 
dose based on the difference of measured 
which corrects for the volume of distribution. 
and testing was important to help with 
monitoring the patient. Discussions with the 
laboratory personnel allowed them to have 
adequate reagent on hand to do the number of 
tests needed and the understand the limitations 
of the assay, such as the presence of heparin 
interfering with assay results. As well, it is 
important to consider all potential sources of 
coagulopathy during surgery, especially the 
dilutional and consumptive processes that are 
inherent to the use of CPB. Discussion with 
the perfusion team was important to limit the 
given on CPB as they would likely impact the 
population to ensure their safety during 
cardiac surgery remains.
The mainstay treatment for patient with 
hemophilia undergoing surgery is replacement 
concentrates.7
level to 80-100% of normal is preferred prior 
to incision to achieve adequate hemostatis.8 
undergoing cardiothoracic surgery, once 
adequate hemostasis is achieved via a 
combination of bolus and continuous infusion 
from patients without hemophilia. This 
experience demonstrated the importance 
of multidisciplinary consultation and 
preoperative planning for the care of complex 
patients undergoing major surgery. 
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